Tag Archive for: Ona Therapeutics

Weekly roundup: Big ideas, bold moves, and the future of biotech

Last week, Optimum hosted its 17th Annual Healthcare Investor Conference 2025. Held in the heart of London, the event brought together a powerhouse of industry leaders, investors, innovators, and communicators to exchange ideas, explore the market outlook, and tackle the pressing questions facing the life sciences sector.  If you missed the day, or just want […]

Ona Therapeutics Appoints Oncology Drug Development Veteran Dr. Antoine Yver as Chair to Accelerate ADC Programs to Clinical Inflection Points

Brings over 35 years of oncology drug development experience, including senior executive leadership roles at AstraZeneca and Daiichi Sankyo Led the development and approval of multiple breakthrough medicines such as ENHERTU®, TAGRISSO®, and LYNPARZA® Strengthens Ona’s transition to a clinical-stage company with ONA-255, while advancing its pipeline of first-in-class ADCs targeting major solid tumors Barcelona, […]

ONA Therapeutics Announces the Appointment of Dr Pamela Klein to its Board of Directors

Leading medical oncologist and seasoned biotechnology executive with significant experience in drug development  Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Read more…

Optimum’s clients are at the forefront of Cancer research

  World Cancer Day is a moment when all of us stop and think of the impact that cancer has on our lives. As the second-leading cause of death worldwide, with 10 million people dying from cancer every year, cancer is a very present healthcare threat. [tag] Macmillan Cancer Support estimates that there are currently […]